{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Rheumatoid Arthritis",
            "NStudiesAvail": 430108,
            "NStudiesFound": 18,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 18,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Mojgan Mohammadi, Ph.D"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 15, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Percentage change in regulatory T cells from baseline which is analysed by fluorescence-activated cell sorting (FACS)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Effect of mesenchymal stem cells therapy on the percentage of regulatory T cells"
                        ],
                        "NCTId": [
                              "NCT03333681"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "Mingyuan Wu, MD,PhD",
                              "Yongjun Liu, MD,PhD",
                              "Liming Wang, MD",
                              "Haijie Ji, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator",
                              "Study Director",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Adverse Events will be recorded in a patient or clinical investigation subject who administers MSC and will be evaluated a causal relationship with the treatment."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of MSC treatment."
                        ],
                        "NCTId": [
                              "NCT01547091"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Zhong Z Ye, Professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "According to National Cancer Institute Common Terminology Criteria for Adverse Events\uff08NCI-CTCAE)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Severity of adverse events"
                        ],
                        "NCTId": [
                              "NCT02643823"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "Hamid Gourabi, PhD",
                              "Nasser Aghdami, MD,PhD",
                              "Mohsen Emadedin, MD",
                              "Farhad gharibdoost, MD",
                              "Soraya Shadmanfar, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Director",
                              "Study Director",
                              "Study Director",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluation the pain reduction after mesenchymal stem cell transplantation that measured by VAS scaling.",
                              "evaluation the improvement of physical activity after mesenchymal stem cell transplantation that measured by WOMAC scoring.",
                              "Evaluation the walking distance after mesenchymal transplantation."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "pain",
                              "physical activity",
                              "walking distance"
                        ],
                        "NCTId": [
                              "NCT01873625"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "Gerardo Castrellon, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with adverse events"
                        ],
                        "NCTId": [
                              "NCT01985464"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "Xiaofeng Zeng, M.D., Ph.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Adverse events are assessed by CTCAE 5.0 up to 28\u00b13 days. The flexible change of \u00b13 days is set for the convenience of patients. Day 1 refers to the day the participant accept BC-U001 infusion."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number and frequency of adverse events (AEs)",
                              "Changes of vital signs from 1 hour after infusion to day 28\u00b13",
                              "Changes of complete blood count (CBC) from day 1 to day 28\u00b13",
                              "Changes of blood biochemical from day 1 to day 28\u00b13",
                              "Changes of coagulation function from day 1 to day 28\u00b13",
                              "Routine urine analysis",
                              "Urine pregnancy test (female only)",
                              "Cardiac rate measured by twelve-lead electrocardiogram"
                        ],
                        "NCTId": [
                              "NCT04971980"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The HGB increases by 10g compared to the baseline is considered improvement.",
                              "FVC increases by 0.5% and DLCO increases by 10% compared to baseline are considered improvement."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Improvement rate of blood routine hemoglobin (HGB) compared to baseline.",
                              "Improvement rate of forced vital capacity (FVC) and/or carbon monoxide diffusing capacity (DLCO) compared to baseline."
                        ],
                        "NCTId": [
                              "NCT03798028"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Philip Waller, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "linette@hopebio.org"
                        ],
                        "PointOfContactOrganization": [
                              "Hope Biosciences Stem Cell Research Foundation"
                        ],
                        "PointOfContactPhone": [
                              "346-900-0340"
                        ],
                        "PointOfContactPhoneExt": [
                              "102"
                        ],
                        "PointOfContactTitle": [
                              "Linette Rehkopf RPh"
                        ],
                        "PrimaryCompletionDate": [
                              "August 17, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Total number of Adverse Events and Serious Adverse Events across all subjects over 12 months."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Total Number of Adverse Events and Serious Adverse Events"
                        ],
                        "NCTId": [
                              "NCT03691909"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "Chadwick Prodromos, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Clinical monitoring of possible adverse events or complications"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety (adverse events)"
                        ],
                        "NCTId": [
                              "NCT05003934"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Total number and rate of AEs and SAEs, related and non-related with BX-U001 infusion will be recorded as a measure of tolerability and safety."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Frequency of Adverse Events (AE) and Serious Adverse Events (SAE)"
                        ],
                        "NCTId": [
                              "NCT03828344"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "Nora singer, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 31, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "\u2022 In addition, a DLT will be assigned if through 14 days after the infusion any grade 3-4 adverse event for pulmonary, cardiac, renal, oral mucosal or hepatic, and grade 4 adverse events for other organs occurred per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.",
                              "\u2022 A DLT is triggered by occurrence through 48 hours after infusion of grade \u22652 infusion-related allergic toxicities, which include rash, flushing, urticaria, dyspnea, fever \u226538\u00b0C (\u2265100.4\u00b0F) as scored according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) version 4.03.",
                              "\u2022 Changes in spirometry following infusion compared to baseline",
                              "\u2022 Incidence and severity of adverse events"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety assessed by dose limiting toxicity (DLT)",
                              "Safety assessed by dose limiting toxicity",
                              "Safety assessed by change in spirometry",
                              "Safety assessed by all adverse events"
                        ],
                        "NCTId": [
                              "NCT03186417"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Derek W Guillory, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The total number of adverse events and severe adverse events related and non-related with AdMSCs will be recorded to indicate the safety and tolerability."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Adverse Events and Sever Adverse Events"
                        ],
                        "NCTId": [
                              "NCT04170426"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "measured by VAS scaling"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Evaluation of Pain Reduction measured by VAS scaling"
                        ],
                        "NCTId": [
                              "NCT03067870"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluate the number of adverse events Safety of FURESTEM-RA Inj."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of FURESTEM-RA Inj. - number of adverse events"
                        ],
                        "NCTId": [
                              "NCT03618784"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Fu-Sheng Wang, professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Serum alkaline phosphatase (ALP)"
                        ],
                        "NCTId": [
                              "NCT01662973"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [
                              "Fu-Sheng Wang, professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Liver Histology change",
                              "Serum alanine aminotransferase (ALT)"
                        ],
                        "NCTId": [
                              "NCT01661842"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OverallOfficialName": [
                              "Jos\u00e9 Mar\u00eda Alvaro-Gracia, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Total number of Adverse Events and Severe Adverse Events, related and non-related with the medication will be recorded as a measure of tolerability and safety."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Adverse Events and Severe Adverse Events"
                        ],
                        "NCTId": [
                              "NCT01663116"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OverallOfficialName": [
                              "Christiaan Coetzee, MD",
                              "Mark Myerson, MD",
                              "John Anderson, MD",
                              "Paul Juliano, MD",
                              "Andrew Murphy, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Fusion Rate (%)(as determined by CT assessment)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Fusion Rate (%)(as determined by CT assessment)"
                        ],
                        "NCTId": [
                              "NCT01413061"
                        ]
                  }
            ]
      }
}